References
- 1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34:29-34.10.1016/0002-9149(74)90089-7
- 2. Ren J, Davidoff AJ. Diabetes rapidly induces contractile dysfunctions in isolated ventricular myocytes. Am J Physiol. 1997; 272:H148-H158.
- 3. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: The search for a unifying hypothesis. Circ Res. 2006; 98:596-605.10.1161/01.RES.0000207406.94146.c2
- 4. Bell DS. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care. 1995; 18:708-14.10.2337/diacare.18.5.708
- 5. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994; 43:676-83.10.2337/diab.43.5.676
- 6. Ma H, Li SY, Xu P, Babcock SA, Dolence EK, Brownlee M, et al. Advanced glycation endproduct (AGE) accumulation and AGE receptor up-regulation contribute to the onset of diabetic nephropathy. J Cell Mol Med. 2009; 13:1751-64.10.1111/j.1582-4934.2008.00547.x
- 7. Edelstein D, Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia. 1992; 35:96-7.10.1007/BF00400859
- 8. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia. 1994; 37:32-5.10.1007/BF00428774
- 9. Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia. 1992; 35:946-50.10.1007/BF00401423
- 10. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, et al. Myocyte death in streptozotocininduced diabetes in rats in angiotensin II- dependent. Lab Invest. 2000; 80:513-27.10.1038/labinvest.3780057
- 11. Fukagawa NK, Li M, Liang P, Russell JC, Sobel BE, Absher PM. Aging and high concentrations of glucose potentiate injury to mitochondrial DNA. Free Radical Biol Med. 1999; 27:1437-43.
- 12. Dunn JA, Patrick JS, Thorpe SR, Baynes JW. Oxidation of glycated proteins: age-dependent accumulation of N epsilon-(carboxymethyl)lysine in lens proteins. Biochemistry. 1989; 28:9464-8.10.1021/bi00450a033
- 13. von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation. 1999; 99:2934-41.10.1161/01.CIR.99.22.2934
- 14. Cooper ME. The role of the renin-angiotensinaldosterone system in diabetes and its vascular complications. Am J Hypertension. 2004; 17:16S-20S; quiz A12-14.10.1016/j.amjhyper.2004.08.004
- 15. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355:253-9.
- 16. Ruiz-Ortega M, Lorenzo O, Ruperez M, Egido J. ACE inhibitors and AT(1) receptor antagonists-beyond the haemodynamic effect. Nephrol Dial Transplant. 2000; 15:561-5.
- 17. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329:1456-62.
- 18. Nomoto T, Nishina T, Miwa S, Tsuneyoshi H, Maruyama I, Nishimura K, et al. Angiotensinconverting enzyme inhibitor helps prevent late remodeling after left ventricular aneurysm repair in rats. Circulation. 2002; 106:I115-9.
- 19. Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol. 1993; 3:1531-40.
- 20. Hsu SM, Raine L, Fanger H. Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29:577-80.10.1177/29.4.6166661
- 21. Moreno PR, Murcia AM, Palacio IF, Leon MN, Bernardi VH, Fuster V, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000; 102:2180-4.10.1161/01.CIR.102.18.2180
- 22. Westerman D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, et al. Contributions of cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiuomyopathy.The role of angiotensin receptor antagonism. Diabetes. 2007; 56:641-6.10.2337/db06-1163
- 23. Lavrentyev EN, Estes AM, Malik KU. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res. 2007; 101: 455-64.10.1161/CIRCRESAHA.107.151852
- 24. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation. 2000; 101:2206-12.10.1161/01.CIR.101.18.2206
- 25. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2002; 22:1845-51.10.1161/01.ATV.0000035392.38687.65
- 26. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17betaestradiol through Sp-1 in human vascular endothelial cells. J Biol Chem. 2000; 275:25781-90.
- 27. Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem. 2004; 261:187-91.
- 28. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol. 2002; 13:2478-87.10.1097/01.ASN.0000032418.67267.F2
- 29. Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW. Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon- (carboxymethyl)hydroxylysine in human skin collagen. Biochemistry. 1991; 30:1205-10.10.1021/bi00219a007
- 30. Koka V. Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY. Advanced glycation end products activate a chymase-dependent angiotensin IIgenerating pathway in diabetic complication. Circulation. 2006; 113:1353-6010.1161/CIRCULATIONAHA.105.575589
- 31. Davis BJ, Forbes JM, Thomas MC, Jerums G, Burns WC, Kawachi H, et al. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia. 2004; 47:89-9710.1007/s00125-003-1256-8
- 32. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem. 1991; 266:11649-53.
- 33. Portero-Otin M, Pamplona R, Bellmunt MJ, Ruiz MC, Prat J, Salvayre R, et al. Advanced glycation end product precursors impair epidermal growth factor receptor signaling. Diabetes. 2002; 51:1535-42.10.2337/diabetes.51.5.1535